{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:53:36Z","timestamp":1787756016932,"version":"build-2784847793"},"reference-count":21,"publisher":"American Veterinary Medical Association (AVMA)","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To retrospectively evaluate safety and tolerance of leflunomide for long-term treatment of canine idiopathic immune-mediated polyarthritis (IMPA).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>27 dogs with clinical signs and synovial fluid cytology supportive of IMPA with \u2265 6 months\u2019 follow-up after starting leflunomide.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Medical records were reviewed to identify dogs prescribed leflunomide for treatment of IMPA from February 2012 to May 2022. Initial leflunomide doses of 2 to 4 mg\/kg once daily were prescribed and were titrated to the lowest effective dose with concurrent anti-inflammatory therapy. Complete blood count, serum chemistry, and clinical signs were monitored throughout the course of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Adverse effects potentially attributable to leflunomide noted in 9 of 27 dogs (33%) included vomiting, diarrhea, lethargy, decreased or absent appetite, polyuria and polydipsia, and secondary antibiotic responsive infection and were self-limiting or resolved with outpatient therapy. Alkaline phosphatase (ALP) and alanine aminotransferase (ALT) elevation were documented in all dogs prescribed leflunomide plus prednisone, with persistent liver enzyme elevation in 6 of 9 dogs (67%) and normalization after antibiotic therapy in 3 of 9 dogs (33%). The majority of dogs prescribed leflunomide plus NSAID (11\/17 [65%] dogs) did not experience liver enzyme elevation; 2 of 17 (12%) dogs developed transient antibiotic-responsive liver enzyme elevations, and 4 of 17 (23%) dogs had persistent liver enzyme elevation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Leflunomide was well tolerated for long-term management of IMPA. A significant difference in liver enzyme elevation was identified between dogs prescribed prednisone versus NSAID in combination with leflunomide. Leflunomide with NSAID therapy resulted in less hepatotoxicity compared with leflunomide with prednisone.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.24.01.0032","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T20:45:55Z","timestamp":1712954755000},"page":"1188-1192","source":"Crossref","is-referenced-by-count":9,"title":["Leflunomide with prednisone or nonsteroidal anti-inflammatory drug therapy is safe and tolerated for long-term treatment of immune-mediated polyarthritis in 27 dogs"],"prefix":"10.2460","volume":"262","author":[{"given":"Rebecca B.","family":"Chesne","sequence":"first","affiliation":[{"name":"Blue Pearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Doornink","sequence":"additional","affiliation":[{"name":"Blue Pearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren S. H.","family":"Sri-Jayantha","sequence":"additional","affiliation":[{"name":"Blue Pearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Urie","sequence":"additional","affiliation":[{"name":"Blue Pearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"3","key":"ref1","series-title":"J Am Vet Med Assoc.","first-page":"312","article-title":"Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008)","volume":"236","author":"Colopy SA","year":"2010","unstructured":"Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). J Am Vet Med Assoc. 2010;236(3):312-318. doi:10.2460\/javma.236.3.312"},{"issue":"5","key":"ref2","series-title":"Vet Surg.","first-page":"428","article-title":"A retrospective study of 40 dogs with polyarthritis","volume":"31","author":"Jacques D","year":"2002","unstructured":"Jacques D, Cauzinille L, Bouvy B, Dupre G. A retrospective study of 40 dogs with polyarthritis. Vet Surg. 2002;31(5):428-434. doi:10.1053\/jvet.2002.34665"},{"issue":"6","key":"ref3","series-title":"J Vet Pharmacol Ther.","first-page":"609","article-title":"Leflunomide pharmacokinetics after single oral administration to dogs","volume":"34","author":"Singer LM","year":"2011","unstructured":"Singer LM, Cohn LA, Reinero CR, Papich MG. Leflunomide pharmacokinetics after single oral administration to dogs. J Vet Pharmacol Ther. 2011;34(6):609-611. doi:10.1111\/j.1365-2885.2011.01275.x"},{"issue":"8","key":"ref4","series-title":"Transplantation.","first-page":"1128","article-title":"Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs","volume":"75","author":"Kyles AE","year":"2003","unstructured":"Kyles AE, Gregory CR, Griffey SM,  Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation. 2003;75(8):1128-1133. doi:10.1097\/01.TP.0000061789.97072.12"},{"issue":"8","key":"ref5","series-title":"J Am Vet Med Assoc.","first-page":"1323","article-title":"Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002)","volume":"224","author":"Clements DN","year":"2004","unstructured":"Clements DN, Gear RN, Tattersall J, Carmichael S, Bennett D. Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002). J Am Vet Med Assoc. 2004;224(8):1323-1327. doi:10.2460\/javma.2004.224.1323"},{"issue":"9","key":"ref6","series-title":"Drug Ther Bull.","first-page":"102","volume":"55","author":"Two new drugs for rheumatoid arthritis","year":"2017","unstructured":"Two new drugs for rheumatoid arthritis. Drug Ther Bull. 2017;55(9):102-105. doi:10.1136\/dtb.2017.8.0526"},{"issue":"3","key":"ref7","series-title":"J Vet Intern Med.","first-page":"1206","article-title":"Effects of oral administration of 5 immunosuppressive agents on activated T-cell cytokine expression in healthy dogs","volume":"34","author":"Archer TM","year":"2020","unstructured":"Archer TM, Mulligan C, Narayanan L,  Effects of oral administration of 5 immunosuppressive agents on activated T-cell cytokine expression in healthy dogs. J Vet Intern Med. 2020;34(3):1206-1213. doi:10.1111\/jvim.15729"},{"issue":"2","key":"ref8","series-title":"J Vet Med Sci.","first-page":"265","article-title":"Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds","volume":"78","author":"Fukushima K","year":"2016","unstructured":"Fukushima K, Eguchi N, Ohno K,  Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds. J Vet Med Sci. 2016;78(2):265-269. doi:10.1292\/jvms.15-0129"},{"issue":"4","key":"ref9","series-title":"Can J Vet Res.","first-page":"279","article-title":"Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide","volume":"83","author":"Grobman M","year":"2019","unstructured":"Grobman M, Bishop KA, Rindt H, Nafe LA, Reinero CR. Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide. Can J Vet Res. 2019;83(4):279-284."},{"issue":"10","key":"ref10","series-title":"J Am Vet Med Assoc.","first-page":"1156","article-title":"Clinical features and pathological joint changes in dogs with erosive immune-mediated polyarthritis: 13 cases (2004-2012)","volume":"249","author":"Shaughnessy ML","year":"2016","unstructured":"Shaughnessy ML, Sample SJ, Abicht C, Heaton C, Muir P. Clinical features and pathological joint changes in dogs with erosive immune-mediated polyarthritis: 13 cases (2004-2012). J Am Vet Med Assoc. 2016;249(10):1156-1164. doi:10.2460\/javma.249.10.1156"},{"issue":"4","key":"ref11","series-title":"J Vet Med Sci.","first-page":"437","article-title":"Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in Miniature Dachshunds","volume":"82","author":"Tani A","year":"2020","unstructured":"Tani A, Seno T, Yokoyama N,  Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in Miniature Dachshunds. J Vet Med Sci. 2020;82(4):437-440. doi:10.1292\/jvms.19-0560"},{"issue":"5","key":"ref12","series-title":"Vet Clin North Am Small Anim Pract.","first-page":"1149","article-title":"Update on immununosuppressive therapies for dogs and cats","volume":"43","author":"Viviano KR","year":"2013","unstructured":"Viviano KR. Update on immununosuppressive therapies for dogs and cats. Vet Clin North Am Small Anim Pract. 2013;43(5):1149-1170. doi:10.1016\/j.cvsm.2013.04.009"},{"issue":"8","key":"ref13","series-title":"FASEB J.","first-page":"10132","article-title":"A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases","volume":"34","author":"Wang J","year":"2020","unstructured":"Wang J, Sun J, Hu J,  A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. FASEB J. 2020;34(8):10132-10145. doi:10.1096\/fj.201902793RR"},{"issue":"2","key":"ref14","series-title":"J Small Anim Pract.","first-page":"70","article-title":"Immunomodulatory drugs and their application to the management of canine immune-mediated disease","volume":"52","author":"Whitley NT","year":"2011","unstructured":"Whitley NT, Day MJ. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. J Small Anim Pract. 2011;52(2):70-85. doi:10.1111\/j.1748-5827.2011.01024.x"},{"issue":"3","key":"ref15","series-title":"Reumatol Clin (Engl Ed).","first-page":"133","volume":"15","author":"Alfaro-Lara R","year":"2019","unstructured":"Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA; PRECIS study group, all physicians belong to Division of Internal Medicine, Hospital Central Sur de Pemex. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed). 2019;15(3):133-139. doi:10.1016\/j.reumae.2017.07.011"},{"key":"ref16","article-title":"LiverTox: Clinical and Research Information on Drug-induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548725\/"},{"issue":"2","key":"ref17","series-title":"Vet Med Sci.","first-page":"431","article-title":"A suspected case of a multiple autoimmune syndrome in a Poodle dog","volume":"8","author":"Lim D","year":"2022","unstructured":"Lim D, Jin Y, Son Y, Oh T, Bae S. A suspected case of a multiple autoimmune syndrome in a Poodle dog. Vet Med Sci. 2022;8(2):431-436. doi:10.1002\/vms3.741"},{"issue":"5","key":"ref18","series-title":"J Vet Intern Med.","first-page":"1502","article-title":"A retrospective study on the safety and efficacy of leflunomide in dogs","volume":"31","author":"Sato M","year":"2017","unstructured":"Sato M, Veir JK, Legare M, Lappin MR. A retrospective study on the safety and efficacy of leflunomide in dogs. J Vet Intern Med. 2017;31(5):1502-1507. doi:10.1111\/jvim.14810"},{"key":"ref19","article-title":"In: Plumb\u2019s Veterinary Drug Handbook","author":"Budde JA","unstructured":"Budde JA, McCluskey DM. In: Plumb\u2019s Veterinary Drug Handbook. 10th ed. VetMedux; 2023."},{"issue":"2","key":"ref20","series-title":"Vet Comp Oncol.","first-page":"311","article-title":"Veterinary Cooperative Oncology Group\u2014Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc AK","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT,  Veterinary Cooperative Oncology Group\u2014Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111\/vco.12677"},{"issue":"4","key":"ref21","series-title":"J Vet Intern Med.","first-page":"1325","article-title":"Effects of immunosuppressive agents on the hemostatic system in normal dogs","volume":"32","author":"Thomason JM","year":"2018","unstructured":"Thomason JM, Archer TM, Wills RW, Mackin AJ. Effects of immunosuppressive agents on the hemostatic system in normal dogs. J Vet Intern Med. 2018;32(4):1325-1333. doi:10.1111\/jvim.15132"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/9\/javma.24.01.0032.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/9\/javma.24.01.0032.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/9\/javma.24.01.0032.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:07:28Z","timestamp":1741352848000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/9\/javma.24.01.0032.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":21,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.2460\/javma.24.01.0032","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}